Digital Diagnostics

Digital Diagnostics is a pioneering AI diagnostics company with a mission to transform the quality, accessibility, and affordability of healthcare. Founded in 2010 by Dr. Michael Abramoff, an ophthalmologist, neuroscientist, and computer engineer, the company has developed a patented biomarker-based approach to build autonomous algorithms that make clinical decisions without human intervention. Its flagship product IDx-DR is an autonomous AI system FDA-authorized to diagnose diabetic retinopathy and diabetic macular edema, demonstrating that intelligent diagnostic platforms can be used safely, efficiently, and equitably to improve patient outcomes. The company's recent $75.00M Series B investment at 23 August 2022, led by 8VC, KKR, Optum Ventures, Gundersen Lutheran, Kinderhook, University of Iowa, Cedar Pine, Edward-Elmhurst Health, OSF Ventures, indicates substantial support and confidence from investors in its innovative approach. With a focus on healthcare, based in the United States, Digital Diagnostics is paving the way for automated diagnosis to become a new standard of care, promising to significantly contribute to democratizing healthcare.